Antimutagenic activity of todralazine and fluphenazine. A comparison of the results from short-term cytogenetic tests

• Autorzy: Gasiorowski K.
• Języki publikacji: EN

Abstrakty

EN

The multicriterial analysis proved that the antimutagenic effect fluphenazine exerted on human blood cells cultured in the presence of the standard mutagens was 60-time stronger than the effect exerted by todralazine. Future attempts to obtain chemical derivatives of fluphenazine should yield compounds which possess the antimutagenic activity but manifest a low or none psychotropic action.

Słowa kluczowe

EN

fluphenazine; antimutagenic activity; blood cell; man; todralazine; multicriterial analysis

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2000
• Tom: 05
• Numer: 3
• Opis fizyczny: p.397-403,fig.

Twórcy

autor

Gasiorowski K.

• Wroclaw Medical University, 14 Kochanowskiego Str., 51-601 Wroclaw, Poland

Bibliografia

• 1. DeFlora, S. and Ramel, C. Mechanisms of inhibitors of mutagenesis and carcinogenesis. Classification and overview. Mutat. Res. 202 (1988) 285- 306.
• 2. Waters, M. D., Brady, A. L., Stack, H.F. and Brockman, H. E. Antimutagenicity profiles for some model compounds. Mutat. Res. 238 (1990) 57-85.
• 3. DeFlora S. Mechanisms of inhibitors of mutagenesis and carcinogenesis. Mutat. Res. 402 (1998) 151-158.
• 4. Livero, L. and von Borstel, R. C. The 4th International Conference on Mechanisms of antimutagenesis and anticarcinogenesis. A summary. Mutat. Res. 350 (1996) 287-293.
• 5. Mitscher, L. A., Talikepalli, H., McGhee, E. and Shankel, D. M. Natural antimutagenic agents. Mutat. Res. 350 (1996) 143-152.
• 6. Gąsiorowski, K. and Brokos B. The antimutagenic activity of two plant- derived compounds. A comparative cytogenetic study. Cell. Mol. Biol. Lett. 5 (2000) 171-190.
• 7. Kelloff, G. J., Boone, C. W., Steele, V. E., Crowell, J. A., Lubert, R. and Sigmann, C. C. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res. 54 (suppl.) (1994) 2015s-2024s.
• 8. Ramel, C., Alekperov, U. K., Ames, B. N., Kada, T. and Wattenberg, L. W. Inhibition of mutagenesis and their relevance to carcinogenesis. Mutat. Res. 168 (1986) 47-65.
• 9. Gąsiorowski, K., Szyba K. and Urban, J. Todralazine influence upon the mutagenicity of some direct- and indirect-acting mutagens. Mutat. Res. 324 (1994) 133-137.
• 10. Gąsiorowski, K. and Brokos, B. Evaluation of antimutagenic effect of todralazine in cultured lymphocytes. Mutagenesis 15 (2000) 137-141.
• 11. Gąsiorowski, K., Brokos, B., Szyba, K. and Leszek J. Antimutagenic activity of fluphenazine in the standard short-term tests. Mutagenesis 16 (2000) in press.
• 12. Bellinger, B. Quantifizierung, Bewerung und Bestgestalltung betrieblicher Rechtsbeziehungen. Berliner Wissentschaftliche Gesellschaft E. V., Jahrbuch, 1978.
• 13. Melnick, R. L., Huff, J., Barret, J. C., Maronpont, R. R., Lucier, G. and Portier, C. J. Cell proliferation and chemical carcinogenesis: Symposium overview. Environ. Hlth Perspect. 101 (suppl.5) (1993) 3-8.
• 14. Kaston, M. B. and Kuerbitz, S. J.: Control of G1 arrest after DNA damage. Environ. Hlth Perspect. 101 (suppl.5) (1993) 55-58.
• 15. Tomatis, L. Cell proliferation and carcinogenesis: a brief history and current view based on a IARC Workshop Report. Environ. Hlth Perspect. 101 (suppl.5) (1993) 149-152.
• 16. Ames, B. N., Shinegaga, M. K. and Gold, L. S. DNA lesions, inducible DNA repair and cell division: the key factors in mutagenesis and carcinogenesis. Environ. Hlth Perspect. 101 (suppl.5) (1993) 35-44.
• 17. Cavalieri, E. L. and Rogan, E. G. The approach to understanding aromatic hydrocarbon carcinogenesis. The central role of radical cation in metabolic activation. Pharmacol. Ther. 55 (1992) 183-199.
• 18. Goldstein, J. A. and Faletto, M. B. Advances in mechanisms of activation and deactivation of environmental chemicals. Environ. Hlth Perspect. 100 (1993) 169-176.
• 19. Troll, W. and Weisner, R. The role of oxygen radicals as a possible mechanisms of tumor promotion. Annu. Rev. Pharmacol. Toxicol. 25 (1985) 509-528.
• 20. Frenkel, K. Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmacol. Ther. 53 (1992) 127-166.